Literature DB >> 25053197

Upper limit of cancer extent on biopsy defining very low-risk prostate cancer.

Ola Bratt1,2, Yasin Folkvaljon3, Stacy Loeb4, Laurence Klotz5, Lars Egevad6, Pär Stattin7.   

Abstract

OBJECTIVE: To investigate how much Gleason pattern 3 cancer prostate biopsy specimens may contain without an increased risk of undetected more aggressive cancer, compared with the risk for cancers fulfilling the National Comprehensive Cancer Network (NCCN) criteria for very low-risk prostate cancer. PATIENTS AND METHODS: We identified 1286 men aged <70 years in the National Prostate Cancer Register of Sweden who underwent primary radical prostatectomy (RP) for stage T1c or T2 prostate cancer with Gleason pattern ≤3 only, prostate-specific antigen (PSA) level of <10 ng/mL and a PSA density of <0.15 ng/mL/mL. The association between the extent of cancer in the biopsies (the number and proportion of positive cores and the total cancer length in the cores in millimetres) and the likelihood of Gleason pattern 4-5 in the RP specimen was analysed with logistic regression.
RESULTS: In all, 438 (34%) of the 1286 men had Gleason pattern 4-5 in the RP specimen. Increasing number and proportion of positive biopsy cores, as well as increasing biopsy cancer length were both significantly associated with increased risk of upgrading at RP in univariable analysis, but in multivariable analysis only biopsy cancer length remained significant. The 684 men with stage T1c and <8 mm cancer had similar risk of upgrading regardless of whether the number of positive biopsy cores was 1-2 or 3-4 (28% vs 27% risk); upgrading was more common among the remaining men (40%, P < 0.01).
CONCLUSIONS: Men aged <70 years with stage T1c prostate cancer and 3-4 biopsy cores with Gleason pattern 3 are not more likely to have undetected Gleason pattern 4-5 cancer than men with 1-2 cores with cancer, provided that the total biopsy cancer length is <8 mm. We propose that the definition of very low-risk prostate cancer is widened accordingly.
© 2014 The Authors BJU International © 2014 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biopsy; categorisation; pathology; prostatic neoplasms

Mesh:

Year:  2015        PMID: 25053197     DOI: 10.1111/bju.12874

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

2.  Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.

Authors:  Frederik B Thomsen; Yasin Folkvaljon; Klaus Brasso; Stacy Loeb; David Robinson; Lars Egevad; Pär Stattin
Journal:  J Surg Oncol       Date:  2016-08-11       Impact factor: 3.454

3.  Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Authors:  Stacy Loeb; Yasin Folkvaljon; Caitlin Curnyn; David Robinson; Ola Bratt; Pär Stattin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

4.  The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.

Authors:  Lucy A M Simmons; Abi Kanthabalan; Manit Arya; Tim Briggs; Dean Barratt; Susan C Charman; Alex Freeman; James Gelister; David Hawkes; Yipeng Hu; Charles Jameson; Neil McCartan; Caroline M Moore; Shonit Punwani; Navin Ramachandran; Jan van der Meulen; Mark Emberton; Hashim U Ahmed
Journal:  Br J Cancer       Date:  2017-03-28       Impact factor: 7.640

5.  Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.

Authors:  Eugenio Ventimiglia; Anna Bill-Axelson; Ola Bratt; Francesco Montorsi; Pär Stattin; Hans Garmo
Journal:  JAMA Netw Open       Date:  2022-09-01

Review 6.  Active surveillance and focal therapy for low-intermediate risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Transl Androl Urol       Date:  2015-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.